Research Analysts Set Expectations for Roche FY2026 Earnings

Roche Holding AG (OTCMKTS:RHHBY) – Erste Group Bank lifted their FY2026 EPS estimates for Roche in a research report issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $3.15 per share for the year, up from their previous estimate of $3.10. The consensus estimate for Roche’s current full-year earnings is $3.05 per share. Erste Group Bank also issued estimates for Roche’s FY2027 earnings at $3.41 EPS.

A number of other research analysts also recently weighed in on the stock. Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 target price for the company in a research report on Friday. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, HSBC lowered Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Five analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $60.00.

Roche Stock Performance

Shares of RHHBY stock opened at $57.43 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche has a 52 week low of $37.51 and a 52 week high of $60.85. The firm’s 50-day simple moving average is $52.27 and its two-hundred day simple moving average is $52.90.

Institutional Trading of Roche

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Puzo Michael J bought a new position in Roche in the 2nd quarter worth about $1,229,000. Fulton Bank N.A. lifted its holdings in shares of Roche by 5.1% in the second quarter. Fulton Bank N.A. now owns 11,572 shares of the company’s stock worth $597,000 after buying an additional 559 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Roche by 14.3% in the second quarter. GAMMA Investing LLC now owns 29,015 shares of the company’s stock valued at $1,490,000 after acquiring an additional 3,625 shares during the period. Confluence Investment Management LLC increased its holdings in Roche by 1.2% during the 2nd quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock worth $1,074,000 after acquiring an additional 258 shares during the period. Finally, McIlrath & Eck LLC bought a new position in Roche in the 1st quarter valued at $39,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.